Cumberland Pharmaceuticals (CPIX) EBITDA (2010 - 2026)

Cumberland Pharmaceuticals has disclosed EBITDA across 17 years of filings, most recently posting -$3.1 million for Q1 2026.

• EBITDA for Q1 2026 came in at -$3.1 million, down 342.22% year-over-year; the trailing twelve-month figure through Mar 2026 was -$7.2 million (down 120.51% YoY), and the FY2025 annual result was -$2.8 million, up 56.59% from the prior year.
• EBITDA came in at -$3.1 million for Q1 2026 at Cumberland Pharmaceuticals, down from -$1.4 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $1.3 million in Q1 2025 to a low of -$6.2 million in Q4 2023.
• The 5-year median for EBITDA is -$1.7 million (2024), against an average of -$1.6 million.
• Across the five-year window, EBITDA plunged 4591.4% in 2024 and jumped 169.12% in 2025, its largest moves.
• Cumberland Pharmaceuticals' EBITDA stood at -$2.3 million in 2022, then tumbled by 171.28% to -$6.2 million in 2023, then surged by 70.19% to -$1.8 million in 2024, then gained by 25.56% to -$1.4 million in 2025, then plunged by 128.22% to -$3.1 million in 2026.
• The last three EBITDA figures came in at -$3.1 million (Q1 2026), -$1.4 million (Q4 2025), and -$2.0 million (Q3 2025), per Business Quant data.